Skip to main content

Table 1 FDA Adverse Event Reporting System analysis case demographics

From: A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors

Characteristics n (%)
Total 90,740
Age 63 (53–70)
Sex
 Male 41,162 (45.4%)
 Female 49,578 (54.6%)
Weight (kg) 73.5 (59.8–84.0)
Cardiac Adverse Events 8300 (9.1%)
 Myocarditis 345 (0.4%)
 Pericarditis 143 (0.2%)
 Heart Failure 1706 (1.9%)
 Myocardial Infarction 1594 (1.8%)
 Arrhythmias 3858 (4.3%)
 Coronary Artery Disease 654 (0.7%)
Anti-inflammatory medication use 18,797 (20.7%)
Cardioprotective medication use 23,372 (25.8%)
Treatment groups
 anti-PD-(L)1 18,536 (20.4%)
 anti-CTLA4 1855 (2%)
 combination immunotherapy 4442 (4.9%)
 Chemotherapy 65,907 (72.6%)
  1. PD-(L)1 = Programmed cell death protein -1 and Programmed death ligand -1 therapies; CTLA = cytotoxic T-lymphocyte-associated protein 4